Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody
Identifieur interne : 000013 ( PascalFrancis/Curation ); précédent : 000012; suivant : 000014Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody
Auteurs : T. Würdinger [Pays-Bas] ; M. H. Verheije [Pays-Bas] ; M. Raaben [Pays-Bas] ; B. J. Bosch [Pays-Bas] ; C. A. M. De Haan [Pays-Bas] ; V. W. Van Beusechem [Pays-Bas] ; P. J. M. Rottier [Pays-Bas] ; W. R. Gerritsen [Pays-Bas]Source :
- Gene therapy : (Basingstoke) [ 0969-7128 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
To explore the potential of using non-human coronaviruses for cancer therapy, we first established their ability to kill human tumor cells. We found that the feline infectious peritonitis virus (FIPV) and a felinized murine hepatitis virus (fMHV), both normally incapable of infecting human cells, could rapidly and effectively kill human cancer cells artificially expressing the feline coronavirus receptor aminopeptidase N. Also 3-D multilayer tumor spheroids established from such cells were effectively eradicated. Next, we investigated whether FIPV and fMHV could be targeted to human cancer cells by constructing a bispecific single-chain antibody directed on the one hand against the feline coronavirus spike protein - responsible for receptor binding and subsequent cell entry through virus-cell membrane fusion - and on the other hand against the human epidermal growth factor receptor (EGFR). The targeting antibody mediated specific infection of EGFR-expressing human cancer cells by both coronaviruses. Furthermore, in the presence of the targeting antibody, infected cancer cells formed syncytia typical of productive coronavirus infection. By their potent cytotoxicity, the selective targeting of non-human coronaviruses to human cancer cells provides a rationale for further investigations into the use of these viruses as anticancer agents.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000046
Links to Exploration step
Pascal:05-0422331Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody</title><author><name sortKey="Wurdinger, T" sort="Wurdinger, T" uniqKey="Wurdinger T" first="T." last="Würdinger">T. Würdinger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Verheije, M H" sort="Verheije, M H" uniqKey="Verheije M" first="M. H." last="Verheije">M. H. Verheije</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Raaben, M" sort="Raaben, M" uniqKey="Raaben M" first="M." last="Raaben">M. Raaben</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Bosch, B J" sort="Bosch, B J" uniqKey="Bosch B" first="B. J." last="Bosch">B. J. Bosch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="De Haan, C A M" sort="De Haan, C A M" uniqKey="De Haan C" first="C. A. M." last="De Haan">C. A. M. De Haan</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Van Beusechem, V W" sort="Van Beusechem, V W" uniqKey="Van Beusechem V" first="V. W." last="Van Beusechem">V. W. Van Beusechem</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Rottier, P J M" sort="Rottier, P J M" uniqKey="Rottier P" first="P. J. M." last="Rottier">P. J. M. Rottier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Gerritsen, W R" sort="Gerritsen, W R" uniqKey="Gerritsen W" first="W. R." last="Gerritsen">W. R. Gerritsen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0422331</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0422331 INIST</idno><idno type="RBID">Pascal:05-0422331</idno><idno type="wicri:Area/PascalFrancis/Corpus">000046</idno><idno type="wicri:Area/PascalFrancis/Curation">000013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody</title><author><name sortKey="Wurdinger, T" sort="Wurdinger, T" uniqKey="Wurdinger T" first="T." last="Würdinger">T. Würdinger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Verheije, M H" sort="Verheije, M H" uniqKey="Verheije M" first="M. H." last="Verheije">M. H. Verheije</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Raaben, M" sort="Raaben, M" uniqKey="Raaben M" first="M." last="Raaben">M. Raaben</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Bosch, B J" sort="Bosch, B J" uniqKey="Bosch B" first="B. J." last="Bosch">B. J. Bosch</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="De Haan, C A M" sort="De Haan, C A M" uniqKey="De Haan C" first="C. A. M." last="De Haan">C. A. M. De Haan</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Van Beusechem, V W" sort="Van Beusechem, V W" uniqKey="Van Beusechem V" first="V. W." last="Van Beusechem">V. W. Van Beusechem</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Rottier, P J M" sort="Rottier, P J M" uniqKey="Rottier P" first="P. J. M." last="Rottier">P. J. M. Rottier</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author><author><name sortKey="Gerritsen, W R" sort="Gerritsen, W R" uniqKey="Gerritsen W" first="W. R." last="Gerritsen">W. R. Gerritsen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country></affiliation></author></analytic><series><title level="j" type="main">Gene therapy : (Basingstoke)</title><title level="j" type="abbreviated">Gene ther. : (Basingstoke)</title><idno type="ISSN">0969-7128</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Gene therapy : (Basingstoke)</title><title level="j" type="abbreviated">Gene ther. : (Basingstoke)</title><idno type="ISSN">0969-7128</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bispecific antibody</term><term>Coronavirus</term><term>Epidermal growth factor receptor</term><term>Gene therapy</term><term>Human</term><term>Malignant tumor</term><term>Single chain antibody</term><term>Targeting</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ciblage</term><term>Homme</term><term>Anticorps bispécifique</term><term>Anticorps simple chaîne</term><term>Thérapie génique</term><term>Tumeur maligne</term><term>Coronavirus</term><term>Récepteur EGFR</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To explore the potential of using non-human coronaviruses for cancer therapy, we first established their ability to kill human tumor cells. We found that the feline infectious peritonitis virus (FIPV) and a felinized murine hepatitis virus (fMHV), both normally incapable of infecting human cells, could rapidly and effectively kill human cancer cells artificially expressing the feline coronavirus receptor aminopeptidase N. Also 3-D multilayer tumor spheroids established from such cells were effectively eradicated. Next, we investigated whether FIPV and fMHV could be targeted to human cancer cells by constructing a bispecific single-chain antibody directed on the one hand against the feline coronavirus spike protein - responsible for receptor binding and subsequent cell entry through virus-cell membrane fusion - and on the other hand against the human epidermal growth factor receptor (EGFR). The targeting antibody mediated specific infection of EGFR-expressing human cancer cells by both coronaviruses. Furthermore, in the presence of the targeting antibody, infected cancer cells formed syncytia typical of productive coronavirus infection. By their potent cytotoxicity, the selective targeting of non-human coronaviruses to human cancer cells provides a rationale for further investigations into the use of these viruses as anticancer agents.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0969-7128</s0></fA01><fA03 i2="1"><s0>Gene ther. : (Basingstoke)</s0></fA03><fA05><s2>12</s2></fA05><fA06><s2>18</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody</s1></fA08><fA11 i1="01" i2="1"><s1>WÜRDINGER (T.)</s1></fA11><fA11 i1="02" i2="1"><s1>VERHEIJE (M. H.)</s1></fA11><fA11 i1="03" i2="1"><s1>RAABEN (M.)</s1></fA11><fA11 i1="04" i2="1"><s1>BOSCH (B. J.)</s1></fA11><fA11 i1="05" i2="1"><s1>DE HAAN (C. A. M.)</s1></fA11><fA11 i1="06" i2="1"><s1>VAN BEUSECHEM (V. W.)</s1></fA11><fA11 i1="07" i2="1"><s1>ROTTIER (P. J. M.)</s1></fA11><fA11 i1="08" i2="1"><s1>GERRITSEN (W. R.)</s1></fA11><fA14 i1="01"><s1>Virology Division, Department of Infectious Diseases and Immunology, Utrecht University</s1><s2>Utrecht</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></fA14><fA20><s1>1394-1404</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26274</s2><s5>354000131717160060</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>42 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0422331</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Gene therapy : (Basingstoke)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>To explore the potential of using non-human coronaviruses for cancer therapy, we first established their ability to kill human tumor cells. We found that the feline infectious peritonitis virus (FIPV) and a felinized murine hepatitis virus (fMHV), both normally incapable of infecting human cells, could rapidly and effectively kill human cancer cells artificially expressing the feline coronavirus receptor aminopeptidase N. Also 3-D multilayer tumor spheroids established from such cells were effectively eradicated. Next, we investigated whether FIPV and fMHV could be targeted to human cancer cells by constructing a bispecific single-chain antibody directed on the one hand against the feline coronavirus spike protein - responsible for receptor binding and subsequent cell entry through virus-cell membrane fusion - and on the other hand against the human epidermal growth factor receptor (EGFR). The targeting antibody mediated specific infection of EGFR-expressing human cancer cells by both coronaviruses. Furthermore, in the presence of the targeting antibody, infected cancer cells formed syncytia typical of productive coronavirus infection. By their potent cytotoxicity, the selective targeting of non-human coronaviruses to human cancer cells provides a rationale for further investigations into the use of these viruses as anticancer agents.</s0></fC01><fC02 i1="01" i2="X"><s0>002A31D01D</s0></fC02><fC02 i1="02" i2="X"><s0>002B27D03</s0></fC02><fC02 i1="03" i2="X"><s0>215</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Ciblage</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Targeting</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Blancado</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Anticorps bispécifique</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Bispecific antibody</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Anticuerpo biespecífico</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Anticorps simple chaîne</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Single chain antibody</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Anticuerpo simple cadena</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Thérapie génique</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Gene therapy</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Terapia génica</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Tumeur maligne</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Malignant tumor</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tumor maligno</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2><s5>16</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2><s5>16</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2><s5>16</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Récepteur EGFR</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Epidermal growth factor receptor</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Receptor EGFR</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fN21><s1>290</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000013 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000013 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0422331
|texte= Targeting non-human corona viruses to human cancer cells using a bispecific single-chain antibody
}}
| This area was generated with Dilib version V0.6.33. |  |